300363 Porton Pharma Solutions
- 16.81
- -0.29-1.70%
Porton Pharma Solutions News
Boteng Co., Ltd. (300363.SZ) announced first-quarter results, with a net loss of 94.8708 million yuan, a year-on-year profit to loss
Boteng Co., Ltd. (300363.SZ) released its report for the first quarter of 2024, and the company achieved revenue during the reporting period...
Is Weakness In Porton Pharma Solutions Ltd. (SZSE:300363) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Porton Pharma Solutions (SZSE:300363) has had a rough three months with its share price down 26%. However, a closer look at its sound financials might cause you to think again. Given that fundamenta
Porton Pharma Solutions Ltd. (SZSE:300363) Surges 9.2%; Individual Investors Who Own 39% Shares Profited Along With Insiders
Key Insights Porton Pharma Solutions' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 8 shareholders own 50%
Boteng Co., Ltd. (300363.SZ): A total cost of 19.394,500 yuan to buy back 0.12% of the shares
Gelonghui Co., Ltd. (300363.SZ) announced that as of February 29, 2024, the company had repurchased 660,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.12% of the company's current total share capital. The highest transaction price was 32.00 yuan/share, the lowest transaction price was 27.01 yuan/share, and the total transaction amount was 19.3945 million yuan.
Boteng Co., Ltd. (300363.SZ): 2023 Employee Stock Ownership Plan to Complete Stock Purchase
Gelonghui, Feb. 27丨Boteng Shares (300363.SZ) announced that as of February 27, 2024, the 2023 employee stock ownership plan had purchased a total of 2,099,892 shares of the company's shares through centralized bidding transactions in the secondary market, accounting for 0.38% of the company's total share capital. The total transaction amount was 39,012,787.84 yuan, and the average transaction price was 18.58 yuan/share.
Porton Pharma Solutions (SZSE:300363) Jumps 4.7% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Porton Pharma Solutions Ltd. (SZSE:300363) shareholders might understandably be very concerned that the share price has dropped 32% in the last quarter. But that doesn't change the fact that the re
Boteng Co., Ltd. (300363.SZ) plans to invest no more than 50 million yuan in the Xingze Phase IV Fund to lay out innovative life science enterprises
Boteng Co., Ltd. (300363.SZ) announced that the company plans to use its own funds to pledge an investment of no more than 50 million yuan to participate...
Boteng Co., Ltd. (300363.SZ): Intended to participate in the subscription of investment fund shares
Gelonghui, Feb. 23 | Boteng Co., Ltd. (300363.SZ) announced that the company plans to invest no more than 50 million yuan with its own funds to participate in the Suzhou Xingze Xingyong Emerging Medical Industry Investment Fund Management Partnership managed by Shanghai Xingze Investment Management Co., Ltd., as a limited partner, with a fund size of 15-20 billion yuan. Mainly investing in innovative biomedicine, biotherapy and bioengineering products, including and not limited to macromolecular biopharmaceuticals, small-molecule targeted drugs, cell therapy, gene therapy, etc.; innovative medical devices, including but not limited to innovative consumables and devices; and research
Boteng Co., Ltd. (300363.SZ): Jiangxi Boteng has been re-certified as a high-tech enterprise
Gelonghui Co., Ltd. (300363.SZ) announced that Jiangxi Boteng Pharmaceutical Co., Ltd. (“Jiangxi Boteng”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation.
Boteng Co., Ltd. (300363.SZ): 2023 net profit pre-reduced by 83% — 88%
On January 26, Ge Longhui Co., Ltd. (300363.SZ) announced its 2023 annual performance forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 240 million yuan to 341 million yuan, down 83% — 88% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 285.22 million yuan - 386.22 million yuan, down 80% — 86% from the same period last year; operating income of 3517.4 million yuan to 386,9.14 million yuan, down 45% from the same period last year. In 2023, the company expects to achieve operating income
Minsheng Securities: The policy favors the transfer of overseas drugs to domestic production, optimistic about domestic CDMO leaders
The transfer of drugs produced overseas to domestic production ushered in favorable policies, and China's high-quality production capacity is expected to accelerate its entry into the supply chain of overseas pharmaceutical companies.
Porton Pharma Solutions Ltd.'s (SZSE:300363) Price Is Right But Growth Is Lacking
Porton Pharma Solutions Ltd.'s (SZSE:300363) price-to-earnings (or "P/E") ratio of 13.1x might make it look like a strong buy right now compared to the market in China, where around half of the compan
Boteng Biotech warmly congratulates Enkai Pharmaceutical's NK010 injection for obtaining clinical trial approval for a new drug from the US FDA
SUZHOU, January 23, 2024/PRNewswire/ -- On January 17, 2024, a non-genetically-modified natural killer cell injection (project code NK010) independently developed by Shanghai Enkai Cell Technology Co., Ltd. (“NK010”) obtained approval from the US Food and Drug Administration (FDA) for phase I clinical trials (IND). Currently, this product is the first non-genetically modified allogenetically modified peripheral blood NK cell drug approved by the FDA in China. Boteng Biotech warmly congratulates them on this. NK010 has optimized receptor spectrum, diverse targets, high purity, and universality
Is Porton Pharma Solutions (SZSE:300363) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Boteng shares (300363.SZ): a total cost of 19.394,500 yuan to buy back 660,000 shares
Gelonghui Co., Ltd. (300363.SZ) announced that as of December 31, 2023, the company had repurchased 660,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.12% of the company's current total share capital. The highest transaction price was 32.00 yuan/share, the minimum transaction price was 27.01 yuan/share, and the total transaction amount was 19.3945 million yuan (excluding handling fees).
Boteng Co., Ltd. (300363.SZ): The terminal drug of the service involves a wide range of indications
Glonghui, December 13|Some investors asked Boteng Co., Ltd. (300363.SZ) on the investor interactive platform, “Does the company's service outsourcing include cardiovascular, cerebrovascular, Alzheimer's disease, diabetes, and high blood pressure?” The company replied that the terminal drugs served by the company cover a wide range of indications, and the above fields are covered in the company's history or current service projects.
Individual Investors Are Porton Pharma Solutions Ltd.'s (SZSE:300363) Biggest Owners and Were Hit After Market Cap Dropped CN¥541m
Key Insights Porton Pharma Solutions' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by
Porton Pharma Solutions Ltd.'s (SZSE:300363) Stock Is Going Strong: Is the Market Following Fundamentals?
Porton Pharma Solutions' (SZSE:300363) stock is up by a considerable 27% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more clo
Boteng Co., Ltd. (300363.SZ): Wholly-owned subsidiary passed on-site inspection by the US FDA
Glonghui November 20 | Boteng Co., Ltd. (300363.SZ) announced that its wholly-owned subsidiary, Jiangxi Boteng Pharmaceutical Co., Ltd. underwent on-site inspection by the US Food and Drug Administration (“FDA”) from August 21 to 25, 2023. The inspection covered six major systems, including quality, production, equipment and facilities, laboratory control, materials and packaging labels. Recently, Jiangxi Boteng received an on-site inspection report issued by the FDA, confirming that this inspection has been completed and that Jiangxi Boteng has passed the on-site inspection.
Boteng Biotech and Asco reached a strategic cooperation to help NK cells be applied in cancer prevention, beauty, and anti-aging
Suzhou, November 20, 2023/PRNewswire/ -- On November 20, 2023, Suzhou Boteng Biopharmaceutical Co., Ltd. (hereinafter referred to as Boteng Biotech) announced that it has reached a strategic cooperation with Ascoli (Suzhou) Biotechnology Co., Ltd. (hereinafter referred to as Ascoli) to jointly promote the development and production of NK cells, help development and innovation in the field of gene and cell therapy, and accelerate the application of NK cells in the field of cancer prevention, beauty and anti-aging. Boteng Biotech is committed to providing end-to-end gene and cell therapy CDMO services, covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and live bacteria
Analysis
Price Target
No Data
